Evaluation of a crystalline nanosuspension: Polymorphism, process induced transformation and in vivo studies

International Journal of Pharmaceutics

Volumn 408, Issue 1-2, 2011, Pages 138-151

  Sharma, Puneet ^a,c   Zujovic, Zoran D ^a   Bowmaker, Graham A ^a   Denny, William A ^b   Garg, Sanjay ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

High pressure homogenization; Nanosuspension; Polymorph; Process induced transformation; Solid state; Wet milling

Indexed keywords

ANTINEOPLASTIC AGENT; NANOCRYSTAL; SN 30191; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; THERMOGRAVIMETRY; TISSUE DISTRIBUTION; X RAY DIFFRACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DIFFERENTIAL THERMAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG STABILITY; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE; NANOPARTICLES; PHASE TRANSITION; PYRIMIDINONES; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 79953245079     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.01.032     Document Type: Article

References (22)

1. Alexandridis, P., Holzwarth, J.F., Hatton, T.A., 1994. Micellization of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solutions: thermodynamics of copolymer association. Macromolecules 27, 2414-2425.
2. Buszello, K., Harnisch, S., Muller, R.H., Muller, B.W., 2000. The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with solutol HS 15. Eur. J. Pharm. Biopharm. 49, 143-149.
3. Delaney, J.S., 2005. Predicting aqueous solubility from structure. Drug Discov. Today 10, 289-295. (Pubitemid 40222221)
4. Diehl, K.H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J.M., van de Vorstenbosch, C., 2001. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol. 21, 15-23.
5. Dumortier, G., Grossiord, J.L., Agnely, F., Chaumeil, J.C., 2006. A review of Poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 23, 2709-2728.
6. Galli, C., 2006. Experimental determination of the diffusion boundary layer width of micron and submicron particles. Int. J. Pharm. 313, 114-122.
7. Ganta, S., Paxton, J.W., Baguley, B.C., Garg, S., 2009. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int. J. Pharm. 367, 179-186.
8. Guillory, J.K., 1999. Generation of polymorphs, hydrates solvates and amorphous solids. In: Brittain, H.G. (Ed.), Polymorphism in Pharmaceutical Solids, vol. 95. Marcel Dekker, Inc., New York, pp. 183-226.
9. Gu, C.H., Li, H., Gandhi, R.B., Raghavan, K., 2004. Grouping solvents by statistical analysis of solvent property parameters: implication to polymorph screening. Int. J. Pharm. 283 (1-2), 117-125.
10. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., Mills, G.B., 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004.
11. Keck, C.M., Muller, R.H., 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62, 3-16.
12. Li, P., Zhao, L., 2007. Developing early formulations: practice and perspective. Int. J. Pharm. 341, 1-19.
13. Li, R., Mayer, P.T., Trivedi, J.S., Fort, J.J., 1996. Polymorphism and crystallization behavior of Abbott-79175, a second-generation 5-lipoxygenase inhibitor. J. Pharm. Sci. 85, 773-780.
14. Moriguchi, I., Hirono, S., Liu, Q., Nakagome, I., Matsushita, Y., 1992. Simple method of calculating octanol/water partition coefficient. Chem. Pharm. Bull. 40, 127-130.
15. Rabinow, B., Kipp, J., Papadopoulos, P., Wong, J., Glosson, J., Gass, J., Sun, C.S., Wielgos, T., White, R., Cook, C., Barker, K., Wood, K., 2007. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339, 251-260.
16. Ran, Y., He, Y., Yang, G., Johnson, J.L.H., Yalkowsky, S.H., 2002. Estimation of aqueous solubility of organic compounds by using the general solubility equation. Chemosphere 48, 487-509. (Pubitemid 34650935)
17. Ritschel, W.A., Kearns, G.L., 1998. Binding of drugs to biological material. In: Graubart, J.I. (Ed.), Handbook of Basic Pharmacokinetics. , 5th ed. American Pharmaceutical Association, Washington, DC, pp. 119-133.
18. Sharma, P., Denny, W.A., Garg, S., 2009. Effect of wet milling process on the solid state of indomethacin and simvastatin. Int. J. Pharm. 380, 40-48.
19. Strickley, R.G., 2004. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201-230.
20. Wong, J., Brugger, A., Khare, A., Chaubal, M., Papadopoulos, P., Rabinow, B., Kipp, J., Ning, J., 2008. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 60, 939-954.
21. Yang, G., Ran, Y., Yalkowsky, S.H., 2002. Prediction of the aqueous solubility: comparison of the general solubility equation and the method using an Amended solvation energy relationship. J. Pharm. Sci. 91, 517-533.
22. Zhang, G.G., Gu, C., Zell, M.T., Burkhardt, R.T., Munson, E.J., Grant, D.J., 2002. Crystallization and transitions of sulfamerazine polymorphs. J. Pharm. Sci. 91, 1089-1100.